Intended for healthcare professionals


Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

BMJ 2020; 369 doi: (Published 29 April 2020) Cite this as: BMJ 2020;369:m1107

Linked Research

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events

Linked Editorial

SGLT2 inhibitors and kidney outcomes in the real world